SynthesisBMC pulmonary medicine2026
Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiectasis frequently coexists with other chronic airway diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma, forming clinically significant bronchiectasis-COPD overlap and bronchiectasis-asthma overlap phenotypes. However, the global proportion of COPD and asthma among patients with bronchiectasis has not been comprehensively quantified. This study aimed to estimate the pooled proportion of COPD and asthma in bronchiectasis and to explore potential sources of heterogeneity.
methodsPubMed, Embase, and Web of Science were systematically searched up to January 8, 2026. Studies reporting the proportion of COPD or asthma in adults with bronchiectasis confirmed by high-resolution computed tomography were eligible. Random-effects models were used to calculate pooled proportions. Subgroup analyses and meta-regression were performed to explore heterogeneity. Publication bias was assessed using funnel plots and Egger's test.
resultsFifty-two studies (81,779 patients) were included for COPD and 47 studies (71,605 patients) for asthma. The pooled proportion of COPD among bronchiectasis patients was 18% (95% CI: 14-22%; I² = 99.4%), and the pooled proportion of asthma was 16% (95% CI: 11-20%; I² = 99.3%). Subgroup analyses revealed variations by geographic region, study design, and age. Meta-regression identified female proportion as a statistically significant but weak predictor of asthma prevalence (β = 3.97, 95% CI: 0.91-7.03; P = 0.011), explaining only 10.6% of the between-study heterogeneity. No covariates significantly explained heterogeneity in COPD prevalence. Egger's test showed no significant publication bias (COPD: P = 0.506; asthma: P = 0.153), and sensitivity analyses confirmed the stability of the findings.
conclusionsCOPD and asthma coexist in approximately one-fifth of patients with bronchiectasis, highlighting the importance of systematic assessment for these overlap syndromes. A weak association between female sex and asthma prevalence was observed, but this factor explained only a small fraction of the heterogeneity, indicating that other unmeasured variables are more important determinants. These findings support a more integrated, phenotype-driven approach to the management of chronic airway diseases.
trial registrationPROSPERO registration: CRD42023400445.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.